Personalis (PSNL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earning ...

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Date of Report (Date of earliest event reported): January 7, 2025 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) 6600 Dumbarton Circle Fremont, California 94555 (Address of Principal Executive Offices) (Zip Code) (Commission File Number) (IRS ...

Personalis, Inc. (NASDAQ:PSNL) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Caroline Corner - Investor Relations Chris Hall - Chief Executive Officer & President Aaron Tachibana - Chief Financial & Chief Operating Officer Rich Chen - Chief Medical Officer & Executive Vice President, R&D Conference Call Participants Mark Massaro - BTIG Thomas Flaten - Lake Street Capital Operator Good afternoon, everyone, and welcome to Personalis Third Quarter 2024 Earnings Conference Ca ...

Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -93.94%. A quarter ago, it was expected that this provider of contract research and genomic information would post a loss of $0.34 per share when it actually produced a loss of $0.24, delivering a surprise of 29.41%.Over the la ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware 27-5411038 (State or other juri ...

Exhibit 99.1 1 Personalis Reports Third Quarter 2024 Financial Results 41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway Into First-Half of 2027 FREMONT, Calif. – November 6, 2024 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent ...

teekid It has been nearly a year since my last Personalis (NASDAQ:PSNL) article, where I provided some background on Personalis and discussed how their NeXT Platform holds immense clinical and commercial potential. At that time, I believed PSNL was undervalued considering the ticker was trading at a negative enterprise value and its long-term growth in a $30B+ market. Over the past 11 months, PSNL went from around $1.61 per share and is now trading over $4.00 per share following encouraging Q2 earnings with ...

Shares of Personalis (PSNL) have been strong performers lately, with the stock up 167.7% over the past month. The stock hit a new 52-week high of $4.58 in the previous session. Personalis has gained 105.2% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the 13.4% return for the Zacks Medical - Generic Drugs industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...

Personalis, Inc. (NASDAQ:PSNL) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. After tod ...

Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 29.41%. A quarter ago, it was expected that this provider of contract research and genomic information would post a loss of $0.44 per share when it actually produced a loss of $0.26, delivering a surprise of 40.91%. Over the l ...